Statistics in Practice
Advisory Editor
Stephen Senn
Luxembourg Institute of Health
Founding Editor
Vic Barnett
Nottingham Trent University, UK
Statistics in Practice is an important international series of texts which provide detailed coverage of statistical concepts, methods and worked case studies in specific fields of investigation and study.
With sound motivation and many worked practical examples, the books show in down‐to‐earth terms how to select and use an appropriate range of statistical techniques in a particular practical field within each title's special topic area.
The books provide statistical support for professionals and research workers across a range of employment fields and research environments. Subject areas covered include medicine and pharmaceutics; industry, finance and commerce; public services; the earth and environmental sciences, and so on.
The books also provide support to students studying statistical courses applied to the above area. The demand for graduates to be equipped for the work environment has led to such courses becoming increasingly prevalent at universities and colleges.
It is our aim to present judiciously chosen and well‐written workbooks to meet everyday practical needs. Feedback of views from readers will be most valuable to monitor the success of this aim.
A complete list of titles in this series appears at the end of the volume.
SECOND EDITION
This edition first published 2019
© 2019 John Wiley & Sons Ltd
Edition History
John Wiley & Sons (1e, 2002)
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Susan S. Ellenberg, Thomas R. Fleming, and David L. DeMets to be identified as the authors of this work has been asserted in accordance with law.
Registered Offices
John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd., The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
Editorial Office
9600 Garsington Road, Oxford, OX4 2DQ, UK
For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty
While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data
Names: Ellenberg, Susan S., 1946 - author. | Fleming, Thomas R., 1950 - author. |
DeMets, David L., 1944 - author.
Title: Data monitoring committees in clinical trials : a practical perspective / Susan
S. Ellenberg, Thomas R. Fleming, David L. DeMets.
Other titles: Data monitoring committees in clinical trials
Description: Second edition. | Hoboken, NJ : Wiley, 2019. | Series:
Statistics in practice | Preceded by Data monitoring committees in
clinical trials : a practical perspective / Susan S. Ellenberg, Thomas R.
Fleming, David L. DeMets. 2002. | Includes bibliographical references and
index. |
Identifiers: LCCN 2018043881 (print) | LCCN 2018044429 (ebook) | ISBN
9781119512646 (Adobe PDF) | ISBN 9781119512677 (ePub) | ISBN 9781119512653
(hardcover)
Subjects: | MESH: Clinical Trials Data Monitoring Committees-organization &
administration | Clinical Trials as Topic | Data Collection-methods |
Clinical Trials Data Monitoring Committees-ethics
Classification: LCC R853.C55 (ebook) | LCC R853.C55 (print) | NLM W 20.55.C5
| DDC 610.72/4-dc23
LC record available at https://lccn.loc.gov/2018043881
Cover Design & Image: Wiley
We were gratified by the positive reception given to the First Edition of this book, and believe it remains a useful guide to the principles and practices of clinical trial data monitoring committees. Since the time of its publication, however, there have been a number of new developments that impact on the conduct of these committees. Some of these include guidances issued by regulatory and funding agencies, new types of trial designs that impose new demands as well as limitations on DMC functioning, and many more journal publications addressing DMC issues and illustrating the types of difficult issues that DMCs may face. Thus, several years ago it appeared that an update of the book was needed. In this new edition, we have added material to each chapter to provide the most current information about policies related to DMC operations, to describe experiences of recently published trials relevant to DMC decision‐making, and to address special issues in monitoring trials using newly emerging designs. We have also added a chapter focusing on legal issues affecting DMC members, motivated by increasing concerns about litigation related to clinical research generally.
We are grateful to our many colleagues who have written, and continue to write, about their experiences serving on DMCs for trials that presented challenging situations. These publications inform and enlighten the clinical trials community, especially as they relate to emerging issues in clinical trials, such as new types of clinical trial designs.
The oversight of clinical trials remains an extremely important responsibility. We hope this book will be useful to those engaged in DMC activities, whether as members, sponsors, or investigators reporting to these committees.
The randomized clinical trial has been recognized as the gold standard for evaluation of medical interventions for only half a century (Doll, 1998). Over the past several decades, the increasingly central position of randomized clinical trials in medical research has led to continual advances in the development of methodology for the design, conduct, and analysis of these studies. An enormous body of literature relating to clinical trials methodology is now available, a professional society focusing on clinical trials has been established (Roth, 1980; www.sctweb.org), and a large number of statisticians, clinicians, and epidemiologists consider clinical trials as their primary area of research and/or application.
One area of clinical trials that has received relatively little attention but that can be critical to the ethics, efficiency, integrity, and credibility of clinical trials and the conclusions of such trials is the process of interim monitoring of the accumulating data. To an increasing extent, interim monitoring is becoming the province of formally established committees. While a great deal has been written about statistical methods for interim data monitoring, the practical aspects of who should serve on data monitoring committees (DMCs) or otherwise be involved in the monitoring process, what data should be monitored and how frequently, and what are the necessary and appropriate lines of communication have received limited discussion. Since DMCs are given major responsibilities for ensuring the continuing safety of trial participants, relevance of the trial question, appropriateness of the treatment protocol, and integrity of the accumulating data, it is important to understand the ways in which these committees meet such responsibilities.
A word about terminology. Committees to monitor accumulating data from clinical trials go by a variety of names. The two most frequent of these are probably “data and safety monitoring board” and “data monitoring committee,” but there are many other variations (Ellenberg, 2001). We have arbitrarily selected “data monitoring committee,” in part because of its simplicity and in part because this is the term used by international regulatory authorities (http://www.ifpma.org/ich1.html).
From time to time, papers describing the experience of particular DMCs, as well as papers addressing general approaches for operating and serving on such committees, have been published; a number of these are referenced in Chapter 1.
These papers have provided some valuable insights into the monitoring process. In 1992 an international workshop was held at the National Institutes of Health to discuss different approaches to data monitoring that had been or were being used in a variety of settings, and the proceedings were published as a special issue of the journal Statistics in Medicine (Ellenberg et al., 1993). At this workshop, individuals with substantial practical experience in interim data monitoring reported on their preferred operating models, and there was substantial discussion of the advantages and disadvantages of the different approaches presented. Up to now, those workshop proceedings plus the aforementioned papers have constituted the primary references for those interested in learning about the various operating models in use for DMCs, as well as the diversity of issues these committees may consider.
The use of DMCs has continued to grow, especially with respect to trials sponsored by pharmaceutical companies. The demand for individuals to serve on these committees is high; it is increasingly difficult to ensure that any DMC will include at least some members with prior experience on other DMCs. As individuals with extensive experience coordinating and/or serving on such committees, the authors of this book are frequently asked for advice concerning their operation (from trial organizers/sponsors) and the scope of responsibilities of committee members (from new members of such committees). The increasing interest in these issues led us to believe that a comprehensive reference on the practice of interim data monitoring and the structure and operation of DMCs was needed; that was our primary motivation for writing this book.
The book is intended for those involved with or otherwise interested in the clinical trials process. We expect this group will include statisticians, physicians and nurses, trial administrators and coordinators, regulatory affairs professionals, bioethicists, and patient advocates. The issues are relevant to trials sponsored by government funding agencies as well as by pharmaceutical and medical device companies, although approaches taken may differ in different contexts.
We also believe this book should be of interest to those involved in the evaluation and reporting of trial results – for example, medical journal editors and science journalists for lay publications – as the process of trial monitoring has important implications for the interpretation of results. We have attempted to keep the material non‐technical, so as to make it accessible to as large a part of the clinical trials community as possible.
Every chapter in the book addresses an issue that has been debated among those with DMC experience in different settings. Our intent is to describe the issues clearly as well as to describe the arguments that have been made for and against different approaches that might be taken. We will identify areas where there appears to be a general consensus, and occasionally recommend a particular approach even when there is no widespread consensus on that issue. For the most part, however, our goal is to clarify the types of decisions that must be made in implementing DMCs and not to provide a prescription for their operation. There is no “one size fits all” for DMCs; different models may be needed for different situations.
We begin with some introductory background and some historical notes on the use of DMCs in different contexts. Next, we address the scope of responsibilities that may be assigned to a DMC. Some committees are charged with reviewing outcome data only (or even safety data only); others are asked to review the initial protocol, monitor the conduct of the study by assessing accrual, eligibility, compliance with protocol, losses to follow‐up, and other issues that are ultimately relevant to the value and credibility of a trial. The specific responsibilities delegated to a committee monitoring a particular trial will influence other operational aspects, such as committee composition.
In Chapter 3 we consider the committee membership: what types of expertise should be represented on all committees, other relevant factors in selecting committee members, optimal committee size, methods of selecting committees (and committee chairs). An important issue regarding committee membership that we discuss in some detail is conflict of interest.
Chapter 4 continues the consideration of conflicts of interest in the broader context of the independence of the committee. We discuss what is meant by an “independent” committee, and the potential consequences for the trial and its credibility when the committee's independence is called into question. We also discuss the various types of trials for which independence of the DMC may be most critical.
Chapter 5 deals with one of the most controversial issues relating to the interim monitoring of clinical trial data: the extent to which any interim data, and unblinded interim data in particular, should be released to individuals or groups other than the committee itself. It has been argued that there may be a “need to know” for some groups such as the sponsor or the regulatory authority; it has also been argued there is a “right to know” for participating investigators, study subjects, and the general public. Others believe that limiting access to interim results is essential to the successful completion of clinical trials. This chapter focuses on such debates, and their potential implications for trial integrity.
In Chapter 6 we deal with the logistical issues – how often a committee should meet, how long the meetings need to be, how they are conducted, the content of the report the committee is to consider, the preparation and content of meeting minutes, and a number of other issues. Many groups who regularly sponsor and/or coordinate clinical trials have developed their own approaches to these issues, but these approaches can be quite different, even for similar types of clinical trials. Some might consider these types of issues part of the “minutiae” of clinical trials; our experience, however, is that the quality and reliability of the monitoring process may depend very heavily on just these types of issues.
Chapter 7 addresses the very important but little discussed topic of how the DMC interacts with other trial components. There are many constituencies involved in any given trial, including the sponsor(s), the investigators, the statistical coordinating center, the study steering committee, the institutional review board(s), and of course the patients. There is also a variety of modes of interaction, both formal (e.g. submitting reports) and informal (e.g. attending meetings of other components where unstructured discussion may take place).
Chapter 8 provides an overview of the various statistical approaches for interim monitoring of clinical trial data, and some discussion of why some approaches may be more useful in some circumstances than others. In this chapter, we also discuss the rationale for using these statistical tools in the monitoring process, as they have been widely but not universally adopted by DMCs. This discussion includes consideration of the different philosophies that have been expressed regarding the appropriateness of stopping clinical trials before they have collected all the information that was specified at the outset, a discussion that of necessity brings in the ethical issues that have been brought to bear on this determination.
In Chapter 9 we consider in more detail the monitoring approaches best suited to different types of trial and describe an alternative to an independent monitoring committee that has been found useful in some settings.
Finally, in Chapter 10 we review regulatory considerations that may affect the operation of a DMC. There is very little in the US Code of Federal Regulations concerning DMCs; they are certainly not mandated except in one very limited circumstance. But there are aspects of the regulatory process that are important for DMCs to be familiar with, and there have been occasions when interactions between regulatory authorities and DMCs have occurred. Such interactions raise important questions about where certain responsibilities may optimally reside.
Shortly before this book went to press, the Food and Drug Administration issued a draft guidance document on the establishment and operation of DMCs, and that document is briefly summarized.
The reader will find real‐life examples throughout the book. Many of these examples come from the direct experience of the authors and have not been written about previously; others have been described in prior publications. We hope these examples will demonstrate the types of decisions and dilemmas DMCs frequently face, and the consequent difficulty of establishing a set of fixed rules for the operation of these committees. Our goal with this book is to assist those who establish DMCs, those who serve on them, those who are participating in trials and depending on their judgment, as well as those who read, interpret, and use the results of clinical trials.
The book has benefited enormously from the constructive advice of those who graciously agreed to read drafts and provide comments. Baruch Brody, Lawrence Friedman, Alan Hopkins, Desmond Julian, James Neaton, Stuart Pocock, David Stump, and Janet Wittes reviewed drafts of most chapters and their input led us to make many improvements. Robert Temple, Jay Siegel, Scott Emerson, Tom Louis, Paul Canner, and Jonas Ellenberg provided extremely helpful input on specific chapters. Diane Ames assisted in producing many of the figures.
Sue Parman coordinated much circulation of material, arranged meetings and teleconferences, and assisted with the preparation of several chapters.
Thanks are also due to Helen Ramsey of Wiley, who encouraged the development of this book, and to Wiley editors Sharon Clutton, Siân Jones and Rob Calver for their assistance and collegiality throughout the process. We also appreciate the work of Richard Leigh, our copy editor, for the many modifications he suggested and queries he raised that improved the flow of the book and eliminated errors and ambiguity.
We are indebted to all our colleagues with whom we have served on DMCs, with whom we have worked in preparing reports to DMCs, and who have served on DMCs to which we have reported. Whatever value there may be in these pages derives from the fundamentally collaborative experience of monitoring clinical trial data and the mutual learning that ensues.
We would like to acknowledge partial support from National Institutes of Health grants NIHR37AI129168 (T.F.) and NIHR01CA18332 (D.D).
Finally, we are particularly grateful for the forbearance and support of our families – particularly our spouses, Jonas, Joli, and Kathy – during the process of writing, rewriting, arguing, negotiating, and nitpicking as we made our way to the final manuscript.